Previously, Rotinen et al. (2018) and Guo et al. (2019) showed that the OC2 transcription factor is a master regulator that drives aggressive prostate tumors and androgen insensitivity and activates a neuroendocrine differentiation network. This evidence concerns the gene ONECUT2 and prostate neoplasm.